Myriad Genetics said it detected unauthorized access to its information technology network on Nov. 2 and temporarily halted testing operations and order management systems while it responded. Most systems have since returned to normal, but the company is still investigating the incident, including whether patient records were accessed.
- Myriad began containment and response measures after discovering the intrusion, including resetting certain system credentials.
- The company brought in outside experts to help determine the incident’s nature and scope.
- It has not said that patient information was accessed. That question remains under investigation.
- As of Nov. 5, Myriad said it did not expect the incident to have a material adverse effect on its business.
The immediate operational disruption appears to have eased, with most systems back to normal. The investigation is continuing, so the extent of any patient-data exposure—and any resulting legal, regulatory, reputational or financial consequences—has not yet been determined.